UBS Group Lowers Cooper Companies (NASDAQ:COO) Price Target to $66.00

Cooper Companies (NASDAQ:COO) had its target price lowered by investment analysts at UBS Group from $75.00 to $66.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage currently has a “neutral” rating on the medical device company’s stock. UBS Group’s price objective would suggest a potential upside of 22.41% from the stock’s current price.

Several other equities research analysts have also weighed in on COO. KeyCorp reiterated a “sector weight” rating on shares of Cooper Companies in a research note on Friday, June 5th. Needham & Company LLC cut their target price on Cooper Companies from $86.00 to $73.00 and set a “buy” rating for the company in a research report on Thursday. The Goldman Sachs Group set a $61.00 target price on Cooper Companies in a research report on Wednesday, May 27th. JPMorgan Chase & Co. decreased their price target on Cooper Companies from $80.00 to $71.00 and set a “neutral” rating on the stock in a research note on Friday, June 5th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Cooper Companies in a research report on Friday, September 4th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, nine have given a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $74.33.

Cooper Companies Price Performance

Shares of Cooper Companies stock opened at $53.92 on Thursday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.78 and a current ratio of 1.27. The firm’s 50-day simple moving average is $72.42 and its 200-day simple moving average is $70.02. Cooper Companies has a twelve month low of $51.01 and a twelve month high of $89.83. The firm has a market cap of $10.52 billion, a P/E ratio of 45.22, a price-to-earnings-growth ratio of 1.77 and a beta of 0.82.

Cooper Companies (NASDAQ:COO) last posted its quarterly earnings results on Wednesday, September 9th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.12 by $0.03. Cooper Companies had a net margin of 5.57% and a return on equity of 10.88%. The firm had revenue of $1.07 billion during the quarter, compared to analyst estimates of $1.10 billion. During the same quarter in the prior year, the business posted $0.49 earnings per share. The company’s quarterly revenue was up .5% compared to the same quarter last year. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. As a group, research analysts expect that Cooper Companies will post 4.63 EPS for the current fiscal year.

Cooper Companies announced that its board has approved a stock buyback plan on Wednesday, September 9th that authorizes the company to buyback $3.00 billion in outstanding shares. This buyback authorization authorizes the medical device company to repurchase up to 22.7% of its shares through open market purchases. Shares buyback plans are usually a sign that the company’s board of directors believes its shares are undervalued.

Institutional Investors Weigh In On Cooper Companies

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Avalon Trust Co bought a new stake in shares of Cooper Companies during the second quarter worth $25,000. Root Financial Partners LLC boosted its holdings in Cooper Companies by 104.5% in the fourth quarter. Root Financial Partners LLC now owns 317 shares of the medical device company’s stock valued at $26,000 after acquiring an additional 162 shares during the last quarter. SJS Investment Consulting Inc. increased its position in Cooper Companies by 107.5% in the first quarter. SJS Investment Consulting Inc. now owns 361 shares of the medical device company’s stock worth $26,000 after purchasing an additional 187 shares during the period. Elevation Wealth Partners LLC increased its position in Cooper Companies by 1,136.4% in the second quarter. Elevation Wealth Partners LLC now owns 408 shares of the medical device company’s stock worth $29,000 after purchasing an additional 375 shares during the period. Finally, Continuum Advisory LLC bought a new stake in Cooper Companies during the 2nd quarter worth about $30,000. 24.39% of the stock is owned by institutional investors and hedge funds.

Cooper Companies News Summary

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: COO reported fiscal Q3 adjusted EPS of $1.15, above the $1.11-$1.12 analyst consensus. GAAP EPS was $2.24, helped by a $307.2 million benefit from the favorable completion of a U.K. tax examination. Free cash flow increased 66% to $273 million. CooperCompanies Announces Third Quarter 2026 Results
• Positive Sentiment: The board expanded the share-repurchase authorization from $2 billion to $3 billion, potentially allowing repurchases of up to 22.7% of outstanding shares. Management also said it remains open to strategic alternatives that could create shareholder value. CooperCompanies Completes Strategic Review
• Neutral Sentiment: Third-quarter revenue rose roughly 1% year over year to $1.066 billion, with CooperVision revenue flat at $717 million and CooperSurgical revenue up 2% to $349.2 million. The results show continued profitability but limited underlying growth.
• Negative Sentiment: Revenue missed the approximately $1.10 billion consensus estimate, while fiscal 2026 adjusted EPS guidance was cut to $4.51-$4.55 from expectations near $4.63. Fourth-quarter EPS guidance of $1.05-$1.09 also trails the roughly $1.20 consensus. Analysts Lower Forecasts Following Q3 Results
• Negative Sentiment: CooperCompanies ended its strategic review by retaining CooperSurgical because potential offers were not attractive enough. Investors appear disappointed that the company will not receive sale proceeds, amid valuation pressure from a new non-hormonal IUD competitor and recent fertility-litigation costs.
• Negative Sentiment: Analysts responded by lowering price targets, including Needham to $73 from $86 and Bank of America to $65 from $80. Bank of America maintained a neutral rating, while the forecast reductions reinforced concerns about near-term growth.

Cooper Companies Company Profile

Cooper Companies, Inc is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company develops, manufactures and markets products through two primary business segments: CooperVision and CooperSurgical.

CooperVision specializes in contact lenses, including daily disposable, toric, multifocal, multifocal toric, specialty and myopia-management lenses. Its products are designed to address a range of vision-correction needs, including astigmatism, presbyopia and irregular corneas.